Thermo Fisher Scientific Expands Steriles Manufacturing and Research Capabilities in Asia-Pacific Region
Our Alachua facility incorporates equipment and design concepts that set the standard for process and analytical development for early clinical trials, and ultimately commercial scale CDMO capabilities for these advanced therapies. We develop analytics and processes for the major viral gene transfer vector systems: AAV, Adenoviral, Herpesviral, Lentiviral, and Retroviral, using a range of manufacturing platforms, including adherent and suspension for manufacturing therapeutic vectors using mammalian and insect cell host systems.
95,000-square foot facility with robust process and analytical development, QC testing and manufacturing capacity in support of clinical trials for cell and gene therapies.
Learn more about the specific equipment and capabilities at this site by downloading our complete site fact sheet.